SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,098.29866033 USD and is down -5.65 over the last 24 hours. It is currently trading on 12776 active market(s) with $48,501,391,251.88 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp pullback amid broader tech-market weakness and reported spot ETF outflows is driving discussion, with traders debating whether support will hold or selling will deepen. Bearish calls for further downside contrast with dip-buyers who see the decline as a buying opportunity.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

A sharp semiconductor selloff has put Nvidia in focus as traders worry that political pushback and possible data-center restrictions could slow AI infrastructure spending. The community is split between bears anticipating a broader repricing of AI growth and dip buyers who see the policy fears as overblown and expect data-center demand to persist.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff has fueled debate over whether political pushback after the midterms could slow AI and data-center investment, prompting a wider unwind in technology and semiconductor stocks. Bears warn of further declines, while dip-buyers argue AI demand remains intact and view the drop as a correction; traders also describe unusually high volatility and sharp rebounds.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp QQQ selloff has centered on fears that political opposition or regulation could slow data-center construction and weaken AI-related spending, alongside a broader unwind in tech and semiconductor stocks. Traders are divided between expecting more downside and viewing the drop as an oversold dip-buying opportunity, with volatile rebound attempts adding to the debate.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broad semiconductor selloff as traders worry that post-election policy and data-center concerns could slow AI infrastructure spending. The community is split between viewing the drop as an overreaction despite strong results and demand commentary, and seeing it as a repricing of AI-capex expectations.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs quarterly results and earnings call are driving attention: traders cite rapid AI-cloud growth, a larger backlog and new contracts, while managements delayed deployment timeline and substantial funding needs have fueled concern amid the sharp selloff. Bulls view the call as evidence of strong execution and a possible rebound, while bears focus on debt, dilution risk and whether contracted demand will translate into revenue.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,192,071.85523712. The last known price of Ethereum is 2,238.82507201 USD and is down -7.69 over the last 24 hours. It is currently trading on 14268 active market(s) with $19,113,383,798.40 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is under pressure in a broad crypto-market selloff, with traders pointing to weakness across Bitcoin and other tokens and discussing possible further downside. The community is split between calling the bounce a bull trap and buying the dip; some also speculate that the Binance hack and election-related uncertainty are weighing on sentiment.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,066,653.41685987 with 590,287,398.17769277 in circulation. The last known price of Solana is 90.16976508 USD and is down -6.00 over the last 24 hours. It is currently trading on 1189 active market(s) with $4,764,750,158.24 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas steep slide alongside the broader crypto market has traders debating whether the weakness is a buying opportunity or the start of a deeper correction. Dip-buyers point to oversold conditions and accumulation, while bearish traders focus on failed rebounds, support levels and lingering concern about crypto-market confidence after the Binance security incident.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention over potential dilution from its expanded equity line and resale capacity, which traders fear could keep pressure on the shares even as Hyperliquids HYPE token rises. Bulls argue issuing shares to add HYPE to the treasury can benefit shareholders, while bears focus on the supply overhang and PURRs lagging performance relative to the token.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad AI and neocloud selloff, with traders focused on election-related fears of tighter data-center restrictions and concerns about financing, execution, and returns on heavy infrastructure spending. Some see the decline as an overreaction and are buying the dip, while others worry that debt and delayed or uncertain customer demand leave the business exposed.

statis crypto Watchlist

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of +15.89% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Journey Medical Corporation (DERM) Report Negative Q3 Earnings? What You Should Know

Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates

Stevanato (STVN) delivered earnings and revenue surprises of +5.88% and +3.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD

Equity

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs. 


OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.  


This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Analysts upgraded Coinbase, 4D Molecular Therapeutics, Affirm, Chime Financial and Bullish, raising ratings and price targets.read more...

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal. 

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> stock closed down 22% on Monday and continued to drop on Wednesday and Thursday.&nbsp;</li><li>The current popular treatment for Wet AMD is Regeneron’s Eylea.&nbsp;</li><li>Ocular still plans to file for approval of AXPAXLI in the fourth quarter of 2026.&nbsp;</li></ul>Shares of Ocular Therapeutix Inc (<a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a>) fell 5% on Thursday and are on track for their worst week since April 2024, after two rivals posted positive updates in the crowded market for longer-lasting eye injections.The stock closed down 21% on Monday and continued to drop on Wednesday and Thursday after a brief 3% recovery on Tuesday, as competitors posted positive clinical updates that weighed on optimism around Ocular’s lead drug, AXPAXLI, aimed at treating Wet age-related macular degeneration. &nbsp;<h2 class="st-heading-2">KOD, FDMT Raise The Durability Bar</h2>Wet AMD is a form of vision loss driven by leaky blood vessels under the retina. The standard drug, Regeneron’s Eylea, works, but patients need repeated injections into the eye. The race is on to see how long a dose can last.Kodiak Sciences said earlier this week that its late-stage DAYBREAK study met its main goals. Two experimental drugs, Zenkuda and tabirafusp-ted, matched Eylea on vision after one year in patients who had not been treated before. Researchers measured vision as the change in how many letters a patient could read. Kodiak also said 54% of Zenkuda patients were on a six-month schedule at one year, under strict rules that called for a new shot if any fluid showed up on a scan. The company reported no cases of inflammation inside the eye with Zenkuda and a cataract rate of 0.5%, versus 0.9% with Eylea. It plans to file Zenkuda with the FDA in the fourth quarter. Kodiak shares more than doubled on the update on Monday and are up 160% so far this week.4D Molecular Therapeutics, meanwhile, said the first patients had entered 4SIGHT, a late-stage trial of its one-time gene therapy, 4D-150, in diabetic macular edema, a related disease. Updated two-year data from an earlier study showed lasting gains in vision and retinal swelling, and fewer extra shots than standard Eylea dosing, the company said. 4D-150 is already in late-stage testing for wet AMD.<h2 class="st-heading-2">Ocular’s Own Path Is Unchanged</h2>Ocular’s lead drug, AXPAXLI, is a dissolving implant that slowly releases axitinib inside the eye, aiming for months of control from a single shot. A late-stage study met its main goal in February, and a mid-September meeting with the FDA was described as positive. The company still plans to file in the fourth quarter of 2026, with a possible launch in 2027.RBC Capital Markets analyst Lisa Walter called Monday’s drop overdone, arguing the valuation does not reflect a drug that could reach about $1 billion in sales a few years after launch, and said Ocular still has the best-positioned long-acting treatment, according to a report from Investing.com.<h2 class="st-heading-2">How Did <a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> stock stayed in ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘extremely high.’A Stocktwits user said that the company must be valued at about $6 billion. <a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> is currently valued at about $1.6 billion<stembedurl>https://stocktwits.com/Kylea1/message/665562045</stembedurl>Another user opined that the selloff might increase the chances of a buyout, given the company is a “steal” at its current valuation compared with Kodiak’s market valuation of $6.19 billion.<stembedurl>https://stocktwits.com/dhowe888/message/665561130</stembedurl><a class="mention" data-mention="$OCUL" data-symbol-id="OCUL" href="https://stocktwits.com/symbol/OCUL" target="_blank">OCUL</a> stock has dropped 40% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nktr-stock-eyes-worst-day-in-over-3-years-on-rezpeg-data-william-blair-still-sees-a-durability-edge/cZD0hlzRB0g">NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ocular Therapeutix logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs. 

Kodiak Sciences Inc

Ocular Therapeutix Inc

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Stocktwits

Stocktwits Polls

4D Molecular Therapeutics $FDMT will present at seven investor conferences. 
 
Starting with Guggenheim on Nov 10 at 4:30 p.m. ET and running through Dec 10. 
 
Shares closed at $11.37 on Monday, below the SMA50 and above the SMA200, RSI 41. 
 
More details in our hub. 
 
Not investment advice.

Feed

News

Sentiment

Earnings

Fundamentals

Info

FDMT 4D Molecular Therapeutics Inc

Fundamentals

Latest FDMT News